I believe the CEO is pursuing sale of the DEP cancer drug platform the sale will include all current in house drugs along with a large patent portfolio and listed applications. The sale will create a large cash chest for Starpharma to pursue their existing products and applications, the CEO hinted at this possibility in a recent interview. As far as potential value of moneyterizing the platform I am not sure something approaching $400m I would guess. This is just my opinion and not financial advice.
Sale of DEP platform?
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.001(1.01%) |
Mkt cap ! $41.31M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 10.0¢ | $1.725K | 17.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 464483 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 489232 | 1 |
View Market Depth
| Last trade - 10.33am 27/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |